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ABSTRACT Several tumor necrosis factor receptor-
associated factor (TRAF) family proteins including TRAF2,
TRAF3, TRAF5, and TRAF6, as well as Jak3, have been
implicated as potential mediators of CD40 signaling. An
extensive in vitro binding study indicated that TRAF2 and
TRAF3 bind to the CD40 cytoplasmic tail (CD40ct) with much
higher affinity than TRAF5 and TRAF6 and that TRAF2 and
TRAF3 bind to different residues of the CD40ct. Using CD40
mutants incapable of binding TRAF2, TRAF3, or Jak3, we
found that the TRAF2-binding site of the CD40ct is critical for
NF-kB and stress-activated protein kinase activation, as well
as the up-regulation of the intercellular adhesion molecule-1
(ICAM-1) gene, whereas binding of TRAF3 and Jak3 is
dispensable for all of these functions. Overexpression of a
dominantly active IkBa strongly inhibited CD40-induced
NF-kB activation, ICAM-1 promoter activity, and cell-surface
ICAM-1 up-regulation. These studies suggest a potential
signal transduction pathway from the CD40 receptor to the
transcriptional activation of the ICAM-1 gene.
CD40 is a 50-kDa glycoprotein, a member of the tumor
necrosis factor receptor (TNFR) superfamily, and is expressed
on a variety of cells including B cells. Studies with X-linked
hyper-IgM syndrome, a genetic defect in the corresponding
CD40L gene that is expressed predominantly by CD41 T
helper cells, and studies with mice lacking either the CD40 or
CD40L gene, have demonstrated that interaction between
CD40 and CD40L during T and B cell contact is essential for
all events in T cell-dependent antigen responses, including
germinal center formation, Ig isotype switching, antibody
affinity maturation, memory B cell formation, and T cell
activation (1–4). In cell culture systems, stimulation of CD40
receptor with either anti-CD40 antibodies or CD40L rescues B
cells from apoptosis, promotes B cell proliferation, and induces
Ig isotype switching in the presence of cytokines (2).
The pleiotropic biological roles mediated by CD40 raise an
important issue regarding how a single receptor generates
intracellular signals capable of mediating such diverse biolog-
ical phenomena. Studies using yeast two-hybrid screening and
in vitro binding assays have led to the identification of TNFR-
associated factor (TRAF) family proteins 2, 3, 5, and 6 as
proteins associated with CD40 (5–9). In addition, Janus kinase
3 (Jak3) also has been reported recently to associate with the
CD40 cytoplasmic tail (CD40ct) (10). The TRAF family
consists of six known family members, TRAFs 1–6 (1, 5–9,
11–15), which are capable of interacting with various TNF and
non-TNF receptors. Overexpression of TRAFs 2, 5, and 6, but
not TRAFs 1, 3, and 4, in transient transfection experiments
activates both the NF-kB and stress-activated protein kinase
(SAPK) signal transduction pathways (7, 8, 11, 13, 16, 17).
To better understand the contributions of the different
CD40ct-interacting adapter molecules to specific CD40 sig-
naling pathways and CD40-mediated biology, we initiated our
studies by examining the relative binding affinities of TRAFs
2, 3, 5, and 6 and Jak3 with the CD40ct. It was found that the
binding affinities of TRAFs 2 and 3 for the CD40ct are much
greater than those of TRAFs 5 and 6. Using human CD40
mutant constructs that specifically abolish binding of TRAF2,
TRAF3, or Jak3 to the CD40ct, we also found that the
TRAF2-binding site in the CD40ct is required for CD40-
mediated NF-kB and SAPK activation. Finally, we demon-
strate that CD40-mediated up-regulation of ICAM-1, a cell-
adhesion molecule important for cell–cell interactions and
inf lammation, is mediated through NF-kB signaling by
TRAF2.
MATERIALS AND METHODS
Plasmids and Expression Vectors. Full-length wild-type
human CD40 and its mutant derivatives were generated with
PCR end primers and internal primers with appropriate
mutations and cloned into the BamHI and SalI sites of the
pBABEpuro vector (18, 19). Glutathione S-transferase (GST)
fusion proteins all were constructed in the pGex2T prokaryotic
gene fusion expression vector (Pharmacia). The construction
of GST-C17, C10N, C10C, and the full-length GST-mCD40ct
has been described previously (19). Constructs used for the
alanine-scanning mutagenesis were cloned similarly. Expres-
sion was confirmed by Coomassie staining. TRAF constructs
were generated by PCR and cloned into the BamHI and NotI
sites of the PEBB-Flu-tagged mammalian expression vector.
The TRAF2 and TRAF3 templates were derived from con-
structs used previously (19). pME-TRAF5 template used for
PCR was a gift from Jun-ichiro Inoue (University of Tokyo).
The TRAF6 PCR product, generated from a cDNA library,
was digested with BglII and NotI and cloned into the BamHI
and NotI sites of the PEBB-Flu vector. The pGL 1.3, pGL
1.3kB-, and the (kB)3-IFN-LUC luciferase reporters have been
described previously (20, 21). The pBABEpuro CD40L con-
struct has also been described previously (19).
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Cell Culture and Transfection. 293T cells and BOSC pack-
aging cells were maintained in DMEM (GIBCOyBRL) sup-
plemented with 10% fetal bovine serum (FBS) and were
transfected by standard calcium phosphate methods. A549
human lung carcinoma cells, WEHI 231 murine B cell lym-
phoma cells, BI-141 murine T cell hybridoma cell lines, and
Daudi human Burkitt’s lymphoma B cell lines were maintained
in RPMI 1640 medium supplemented with 10% FBS and 1%
penicillinystreptomycin. Transient transfections with reporter
constructs were performed with the Superfect Transfection
Reagent (Qiagen, Chatsworth, CA). Harvested samples were
assessed for luciferase activity by measurement with Promega
luminol substrate. Infections of the BI-141 and WEHI 231 cells
were performed by the use of BOSC packaging cells as
described previously (18, 22). For electroporation, Daudi cells
were electroporated at 250 Vy975 mF and selected with 1
mgyml of active G418 (Mediatech, Washington, DC).
In Vitro Binding Assays, Electrophoretic Mobility-Shift
Assays, and in Vitro Kinase SAPK Assays. GST pull-down
assays were performed as described previously (19). For
gel-shift and SAPK assays, cells were treated as indicated in
the text. Nuclear extracts were prepared and used in binding
reactions with a g-P32-labeled major histocompatibility com-
plex II NF-kB specific hairpin oligonucleotide (20) using
previously published protocols (23). Endogenous SAPK ac-
tivity was assessed by immunoprecipitation with anti-c-Jun
N-terminal kinase 1(JNK1) polyclonal antibodies (Santa Cruz
Biotechnology) using previously published protocols (24).
Fluorescence-Activated Cell Sorter (FACS) Analysis. To
assess expression of the human CD40 constructs, BI-141
infectants and parental cells were stained with fluorescein
isothiocyanate (FITC)-conjugated murine anti-human CD40
mAb (clone 5C3; PharMingen) and analyzed by FACScan flow
cytometer. To assess ICAM-1 induction, WEHI231 or Daudi
cells were stimulated for 24 hr with 1 mgyml of G28.5 or with
soluble CD40L. Samples then were stained with R-
phycoerythrin-conjugated anti-murine ICAM-1 antibodies
(clone 3E2; PharMingen) or FITC-labeled anti-human
ICAM-1 antibodies (PharMingen) and analyzed by FACScan
flow cytometer.
RESULTS
TRAF2 and TRAF3 Bind to the CD40ct with Greater
Affinity than TRAF5 and TRAF6. TRAF2, TRAF3, TRAF5,
and TRAF6 have been shown to bind CD40, based on yeast
two-hybrid assays or in vitro pull-down assays (5–9). To deter-
mine the relative affinities of the TRAF proteins for the
CD40ct, the full-length cDNAs of TRAFs 2, 3, 5, and 6 were
subcloned into the pEBB-Flu vector, which allows for equiv-
alent detectability with antibodies against the Flu-epitope.
When 293T cell extracts overexpressing similar amounts of
TRAF proteins were incubated with GST-tagged human
CD40ct bound to glutathione beads, strong associations were
detected with the CD40ct and TRAFs 2 and 3 whereas the
interactions with TRAF 5 and, especially, TRAF6 were con-
siderably weaker (Fig. 1A).
Experiments similar to those described above were carried
out to test the association of Jak3 with the CD40ct, which had
been reported previously (10). Despite the use of a high-
expression vector, pEBB-Flu-Jak3, we were unable to detect
the precipitation of Jak3 with GST-CD40ct (data not shown).
TRAF2 and TRAF3 Bind Overlapping but Distinct Motifs in
the CD40ct. Because of the very weak interactions of TRAF5
and TRAF6 with the CD40ct and the problems posed by our
ability to detect them, we focused our subsequent efforts on
mapping the binding sites for only TRAF2 and TRAF3 on the
CD40ct with the aim of identifying CD40ct mutants that could
specifically bind either TRAF2 or TRAF3. Using GST pull-
down assays, we previously had identified a 17-aa fragment
(C17) corresponding to amino acid residues 230–246 of the
CD40ct that could bind to TRAF3 as strongly as the entire
CD40ct (19). This C17 peptide also was capable of binding to
TRAF2 as strongly as the full-length CD40ct (Fig. 1B). This
C17 fragment was dissected further into two overlapping
regions corresponding to the first 10 aa (the C10N region) or
the last 10 aa (the C10C region), and the corresponding
fragments were assessed for interactions with TRAFs 2 and 3.
The C10N region was capable of interacting with TRAF2 but
not with TRAF3, whereas the C10C was incapable of inter-
acting with either TRAF2 or TRAF3 (Fig. 1B). These results
suggest that whereas the C17 region within the CD40ct is close
to the minimal-binding motif for TRAF3, the minimal-binding
region for TRAF2 lies within the C10N region.
To further define the binding specificities between TRAF2
and TRAF3, we carried out alanine-scanning mutagenesis to
replace with alanine, one by one, each of the amino acids of the
17-aa fragment in the CD40ct. The GST fusion proteins
containing wild-type C17 and its mutant variants then were
used in the GST pull-down assays to determine the effects of
these mutations on their interactions with TRAF2 and
TRAF3. The mutations that abolished the interaction of
TRAF2 with the C17 region were P230A, V231A, Q232A,
E233A, and T234A (Fig. 2A). All fall within the C10N
fragment. Mutations that abolished TRAF3 binding included
T234A (which also abolished TRAF2 binding), L235A, and
V241A (Fig. 2B). They span the junction of C10N and C10C.
To determine the effects of mutations in the context of
full-length CD40ct, the GST fusion constructs containing the
full-length wild-type CD40ct and full-length CD40ct carrying
mutations such as P207A, Q232A, T234A, and V241A were
examined, and their interaction patterns with TRAF2 and
TRAF3 were observed to be the same as their corresponding
GST-C17 constructs (data not shown). Thus, the binding sites
for TRAF2 and TRAF3 differ significantly, thereby allowing
us to make mutations that can selectively interfere with the
binding of these factors to CD40.
The role of the one amino acid in common for binding
TRAF2 and TRAF3, T234, was studied by mutating it in the
C17 fragment to either serine or valine, generating GST fusion
FIG. 1. Characterization of the relative binding affinities of TRAFs
2, 3, 5, and 6 for the CD40 cytoplasmic tail and determination of the
minimal binding regions within the CD40 C17 region. (A) TRAFs 2
and 3 bind to the CD40ct with much greater affinity than TRAFs 5 and
6. The same amount of glutathione beads bound with the GST-mouse
CD40ct fusion protein was incubated with extracts from 293T cells
transfected with pEBB-Flu TRAF2, pEBB-Flu TRAF3, pEBB-Flu
TRAF5, or pEBB-Flu TRAF6. The beads were washed, and bound
proteins were detected by Western blot analysis with anti-Flu anti-
bodies (Fig. 1A Upper). Equal amounts of extracts (5% of input used
for GST pull-down) were analyzed by Western blot analysis with
anti-Flu antibodies to ensure similar levels of expression of the
different Flu-tagged TRAFs (Fig. 1A Lower). (B) The minimum
binding regions of TRAF2 and TRAF3 within the C17 region are
different. Lysates from 293T cells expressing Flu-TRAF2 or Flu-
TRAF3 were incubated with GST, GST-C17, GST-C10N, or GST-
C10C fusion proteins immobilized on glutathione beads. The bound
proteins then were analyzed by Western blot analysis with anti-Flu
antibodies.
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proteins T234S and T234V. Both TRAF2 and TRAF3 bound
to the T234S mutant as strongly as wild-type C17, whereas the
T234V mutation completely abolished the binding of both
TRAF2 and TRAF3 (Fig. 2C). Serine is one methyl group
shorter than threonine, whereas valine has a methyl group in
the place of threonine’s hydroxyl. Thus, our results demon-
strate that the hydroxyl group of the threonine at position 234
of CD40 is essential for TRAF binding.
Binding of TRAF2 Correlates with CD40-Mediated NF-kB
and SAPK Activation. CD40 has been reported to activate
multiple signal transduction pathways, including ones involv-
ing NF-kB, SAPK, and STAT (10, 24, 25). The cytoplasmic tail
of CD40 associates with multiple downstream signaling medi-
ators such as TRAF2, TRAF3, and, possibly, Jak3. To deter-
mine the roles of TRAF2, TRAF3, and Jak3 in CD40-
mediated NF-kB and SAPK activation, we created full-length
human CD40 variants in the pBABEpuro retroviral vector to
express the wild-type receptor; the Q232A mutant that spe-
cifically abolishes TRAF2 binding; the T234A mutant that
abolishes TRAF2, TRAF3, and Jak3 binding (10); the V241A
mutant that specifically abolishes TRAF3 association; and a
deletion mutant lacking the cytoplasmic tail of the human
CD40 receptor (DC). Also included was a P207A mutant that
was reported to abolish the association of Jak3 with the CD40ct
(10).
BI-141 murine T cell hybridoma cells were retrovirally
infected with the human CD40 and its variants and then
selected with puromycin. These cells were chosen as target
cells because their low-basal NF-kB activity facilitates the
detection of induction by gel-shift assay. The levels of expres-
sion of the exogenous receptors were found to be similar
among the different cell lines as determined by FACScan
analysis (data not shown).
To evaluate the specificity and contributions of TRAF2,
TRAF3, and Jak3 in CD40-mediated signaling, the cell lines
were stimulated with an anti-human CD40 mAb, G28.5, and
activation of the SAPK and NF-kB signaling pathways were
investigated. SAPKyJNK1 activity was assessed by an in vitro
kinase assay that measures the kinase activity of immunopre-
cipitated JNK1 using GST-Jun as the substrate. Nuclear
extracts were processed from the same samples to assess
NF-kB activation by gel-shift analysis using an NF-kB-specific
oligonucleotide probe. The induction of both the SAPKyJNK1
activity and NF-kB activity was evident in the wild-type,
P207A, and V241A human CD40 variants, whereas no induc-
tion was apparent in the Q232A, T234A, and the cytoplasmic
deletion mutants (Fig. 3). Similar assays also were conducted
with the full-length human CD40 variants encoding the P230A,
V231A, E233A, and L235A mutants. Like the Q232A mutant,
which loses TRAF2 binding but retains TRAF3 binding, the
mutants encoding for P230A, V231A, and E233A are unable
to activate the SAPK and NF-kB pathways upon stimulation
with G28.5, whereas the L235A mutant, which loses TRAF3
binding but retains TRAF2 binding, still can activate both
signaling pathways (P.D. and G.C., unpublished results). Cor-
relating binding specificity and activation, it appears that the
roles of TRAF3 and Jak3 in SAPK and NF-kB signaling are
minimal whereas the role of TRAF2 is critical.
Binding of TRAF2 Correlates with CD40-Induced ICAM-1
Up-Regulation. CD40 activation is known to result in the
up-regulation of multiple cell-surface receptors such as CD23,
ICAM-1, FAS, B7, and others (2). To determine the biological
significance of the signaling mediated by TRAFs 2 and 3 and
Jak3, we assayed for the ability of the human CD40 variants to
up-regulate ICAM-1 expression in the murine B cell lym-
phoma cell line, WEHI 231. WEHI 231 cells were retrovirally
infected with constructs expressing the human CD40 and its
variants in the same manner as for the BI-141 cells and then
selected with puromycin. FACS analysis of these infected
WEHI 231 cell lines after overnight treatment with the anti-
human CD40-specific G28.5 antibody showed up-regulation of
ICAM-1 expression in the stable cell lines expressing the
wild-type, P207A, and V241A human CD40 receptors (Fig. 4).
However, cell lines expressing the Q232A, T234A, and cyto-
plasmic deletion mutants did not up-regulate ICAM-1 (Fig. 4).
The levels of the anti-hCD40 antibody-induced ICAM-1 up-
regulation in the WEHI 231 cells were similar to those induced
by CD40L (data not shown), and these results were reproduc-
ible. Thus, CD40-mediated ICAM-1 up-regulation correlates
with the binding of TRAF2, but not TRAF3 or Jak3, to the
CD40ct.
FIG. 3. CD40 mutants that retain TRAF2 binding are capable of
signaling through the NF-kB and SAPKyJNK1 pathways upon acti-
vation. Twenty-five million BI141 cells were either untreated or
treated with 1 mgyml of the murine anti-human CD40 mAb, G28.5, for
30 min, at which point the samples were either processed for NF-kB-
dependent gel-shift assays or for the SAPK-dependent phosphoryla-
tion of GST-Jun.
FIG. 4. CD40 mutants that retain TRAF2 binding are capable of
up-regulating ICAM-1 upon stimulation. Murine Wehi 231 cells
expressing wild-type and mutant variants of human CD40 were either
untreated (shaded) or treated (dark outline) for 24 hr with 1 mgyml of
G28.5. The cells were stained with R-phycoerythrin-conjugated anti-
murine ICAM-1 antibodies and analyzed by FACS.
FIG. 2. Dissection of the CD40ct by alanine-scanning mutagenesis.
(A and B) TRAF2 and TRAF3 contact overlapping but different sets
of amino acid residues in the CD40ct. The same amount of GST
protein and GST fusion proteins containing either wild-type C17 or
one of 17 mutated forms of C17, with 1 aa residue replaced by alanine,
was incubated with 293T cell extracts overexpressing Flu-tagged
TRAF2 (A) or TRAF3 (B). The bound Flu-TRAF2 and Flu-TRAF3
were detected by Western blot analysis using anti-Flu antibody. (C)
The hydroxyl group of the threonine at position 234 is essential for
TRAF binding. The same amounts of GST protein and GST fusion
proteins containing wild-type C17, T234A, T234S, and T234V were
incubated with 293T cell extracts overexpressing Flu-tagged TRAF2
and TRAF3. The bound Flu-TRAF2 and Flu-TRAF3 were detected
by Western blot analysis using anti-Flu antibody.
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CD40-Induced Up-Regulation of ICAM-1 Is NF-kB-
Dependent. Our data suggest that TRAF2 signaling is crucial
for NF-kB and SAPK activation through CD40 and that the
signals generated by TRAF2 are crucial for at least one aspect
of CD40 biology, namely, ICAM-1 induction. To further
understand the role of NF-kB activation in CD40-mediated
ICAM-1 up-regulation, we generated Daudi human B cell
lymphoma lines that overexpressed a dominant-active inhibi-
tor of NF-kBa (IkB-a), containing serine-to-alanine muta-
tions at amino acid positions 32 and 36, that specifically
prevents NF-kB activation (26). The cells were shown to
express the mutant IkB at levels 2- to 3-fold higher than
endogenous IkB-a and were unable to up-regulate NF-kB
activity upon CD40 activation (H.H.L. and G.C., unpublished
results). In examining the inducibility of ICAM-1 upon CD40
activation, it was found that CD40 ligation with G28.5 mark-
edly up-regulated ICAM-1 expression on wild-type, parental
Daudi cells and on control cells transfected with the empty
expression vector (Fig. 5A). However, CD40-induced ICAM-1
up-regulation was abolished in the cells expressing the domi-
nant-active IkB-a (Fig. 5A), supporting the importance of
NF-kB signaling in CD40-mediated ICAM-1 up-regulation.
The transcriptional regulation of ICAM-1 by inflammatory
cytokines has been studied extensively. Through mutational
analysis of the ICAM-1 promoter, it was determined that the
NF-kB-binding site present at 2187 to 2178 relative to the
transcriptional start site is crucial for ICAM-1 up-regulation by
TNF-a, lipopolysaccharide, phorbol 12-myristate 13-acetate,
and interleukin 1 (21). To determine whether CD40-mediated
up-regulation of ICAM-1 required similar cis elements, pGL2
luciferase reporters driven by either a 1.3-kb ICAM-1 59
promoter fragment (extending from 21353 to 29 of the
transcriptional start site, pGL 1.3) or a 1.3-kb promoter
fragment with mutations in the NF-kB-binding site at 2187 to
2178 (from TGGAAATTCC to TctAgATTag, pGL 1.3kB2)
were transiently transfected into A549 human lung carcinoma
cells. The samples also were cotransfected with combinations
of pBABEpuro CD40, pBABEpuro CD40L, pRCCMV IkB-
dominant active construct, and empty vector. As a positive
control, similar transfections also were carried out with the
artificial NF-kB-dependent luciferase reporter construct,
(kB)3-IFN-LUC (19). As expected, a strong induction was seen
with the (kB)3-IFN-LUC reporter upon induction with CD40
and CD40L (Fig. 5B). A 3-fold luciferase induction was
observed with the pGL 1.3 reporter (Fig. 5B); this induction
was suppressed completely with cotransfection with the dom-
inant-active IkB construct, consistent with the results in the
Daudi cells (Fig. 5A). Induction of the luciferase activity,
however, was absent in the pGL 1.3kB2 samples (Fig. 5B),
indicating that the NF-kB-binding site from 2187 to 2178 is
also critical for CD40-mediated ICAM-1 induction.
Our results thus provide a functional link from the CD40
receptor to ICAM-1 up-regulation in which oligomerization of
the receptor activates TRAF2, which, in turn, activates NF-kB,
a transcription factor that may directly be involved in the
transcriptional activation of the ICAM-1 gene. The results,
however, do not rule out the possibility that other components
of TRAF2 signaling, such as SAPK activation, also are in-
volved in ICAM-1 activation.
DISCUSSION
TRAF family proteins are major adapter molecules transduc-
ing signals from the TNF receptor family and other non-TNF
receptors (11, 12, 15, 27). The cytoplasmic tail of CD40 has
been reported to bind to at least four known TRAF proteins—
TRAF2, TRAF3, TRAF5, and TRAF6—based on the yeast
two-hybrid and in vitro GST pull-down assays (5–9). However,
the relative affinities among these four TRAF proteins to the
cytoplasmic tail of CD40 have not been determined. By
constructing these TRAF cDNAs into the same epitope-
tagged vector, we found with an in vitro binding assay that the
interactions of TRAF5 and TRAF6 with the CD40ct are much
weaker than those of TRAF2 and TRAF3, suggesting that
TRAFs 2 and 3 are the main mediators of CD40 signaling.
Using alanine-scanning mutagenesis, we found that TRAF2
and TRAF3 binding to the CD40ct require different subsets of
amino acid residues, even though both TRAFs bind strongly to
a 17-aa domain within the CD40ct. Interestingly, both TRAF2
and TRAF3 require the threonine 234 residue of the CD40ct
for their binding, and our results underscore the importance of
the hydroxyl moiety at the 234 site. Phosphorylation at the
same threonine 234 residue of CD40 has been reported (28),
and its significance needs to be evaluated further.
Another level of signaling specificity arises from the differ-
ent abilities of the TRAF proteins to activate downstream
signal transduction pathways. Overexpression of TRAF2,
TRAF5, and TRAF6 but not TRAF1, TRAF3, and TRAF4 in
293 cells activates both the NF-kB and SAPK pathways (7, 8,
11, 13, 16, 17). Embryonic fibroblast (EF) cells isolated from
TRAF2 knockout mice failed to activate SAPK, but had only
a delayed response in NF-kB activation after stimulation with
TNF-a (29). The discrepancy between the results from tran-
sient transfection assays and those from knockout mouse
FIG. 5. CD40-induced expression of ICAM-1 is regulated through
the NF-kB-dependent signal transduction pathway. (A) CD40-induced
ICAM-1 up-regulation is inhibited by the overexpression of a domi-
nant-active IkB mutant (pCMV IkB dom.-act.). FACS analysis of
Daudi cells and Daudi transfectants (pCMV-IkB dom.-act. or pCMV
vector) after 24 hr of culture with (shaded) or without (unshaded)
CD40L stimulation. The hatched peak represents parent Daudi cells
stained with a nonspecific control antibody. The x and y axes represent
the relative intensity of ICAM-1 expression and relative cell numbers,
respectively. The percentage of ICAM-1 induced cells is indicated in
the upper portion of each histogram. (B) CD40-mediated up-
regulation of a luciferase reporter driven by a 1.3-kb 59 promoter
region of ICAM-1 is dependent on NF-kB binding to a consensus site
located at 2187 to 2178 relative to the transcriptional start site. A549
human lung carcinoma cells were transiently transfected with either
the (kB)3-IFN-LUC reporter, the pGL2 1.3 luciferase reporter, or the
pGL2 1.3kB- reporter, which has a mutated cis element between sites
2187 and 2178. Samples also were cotransfected with combinations
of pBABEpuro hCD40WT, pBABEpuro mCD40L, pRCCMV IkB
dominant-active construct, and empty vector. As a normalization
factor, all samples were cotransfected with 1 mg of pCMVlacZ
reporter, and the y-axis data points represent luciferase data after
correcting for lacZ activity.
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studies in TNF-a-induced activation of the NF-kB pathway
could be due to either the existence of an alternative NF-kB
activation pathway through the TNF receptors or redundancy
of TRAF2 with other TRAF family members. Despite the fact
that TRAF2 and TRAF3 have differing abilities to activate
NF-kB and SAPK, interestingly, the phenotypes of TRAF2
knockout mice are similar to those of TRAF3 knockout mice,
in that they all die about 2 weeks after birth and are depleted
of both T and B lymphocytes (29, 30). Conversely, transgenic
mice overexpressing a truncated form of TRAF2 have in-
creased numbers of B cells, although cells isolated from these
mice behave similarly to EF cells isolated from TRAF2
knockout mice in TNF-mediated NF-kB and SAPK activation
(29, 31). Based on those previously published results, the roles
of TRAF2 in NF-kB signaling and in B cell activation are still
unclear.
Here, we took a different approach by using the results we
obtained from alanine-scanning mutagenesis and making var-
ious stable cell lines expressing mutant CD40 that would
abolish the binding of either TRAF2 or TRAF3. Although we
cannot exclude the possible involvement of other TRAF
proteins or even non-TRAF proteins in CD40-mediated
NF-kB and SAPK activation, the results in both Figs. 1 and 3
suggest that TRAF2 may be involved in both the NF-kB and
SAPK signal transduction pathways, at least in the case of
CD40. The role of TRAF3 in CD40 signaling is not clear. It did
not seem to be involved in CD40-mediated NF-kB and SAPK
activation despite its high affinity for the cytoplasmic tail of
CD40. However, studies using TRAF3 knockout mice indi-
cated that TRAF3 is essential for T-dependent antigen re-
sponses, a function that is defective in CD40 knockout mice.
Therefore, it will be interesting to find out whether TRAF3 or
other TRAF family proteins can activate signal transduction
pathways other than NF-kB and SAPK.
In the past several years, studies using various CD40-
responsive cell lines have identified more than a dozen CD40-
inducible genes, including those encoding for CD23, ICAM-1,
B7.1, B7.2, Bcl-x, cdk4, cdk6, EGFR, A20, and major histo-
compatibility complex II (2, 32, 33). However, it was not clear
which signal transduction pathways are responsible for partic-
ular downstream CD40-inducible genes. We took advantage of
the human-specific CD40 mAb, G28.5, and determined the
effects of various human CD40 mutants upon induction of
CD40-mediated gene expression in murine B cells. Our results
suggest that TRAF2 is not only important for CD40-mediated
NF-kB and SAPK activation, but is also involved in CD40-
mediated up-regulation of the ICAM-1 gene. To further
determine whether the NF-kB or the SAPK pathways are
required for ICAM-1 induction, we made stable B cell lines
overexpressing a mutant IkB, which contains a serine-to-
alanine mutation at the amino acid positions 32 and 36 of IkB.
As a result, CD40 was unable to activate NF-kB and also was
incapable of inducing ICAM-1 up-regulation, demonstrating
that the NF-kB pathway is essential for CD40-mediated
ICAM-1 induction. Our results emphasize the importance of
the NF-kB pathway, but do not exclude the involvement of
other signal transduction pathways such as SAPK or Jaky
STAT in CD40-mediated ICAM-1 induction.
It has been reported that CD40 directly binds to Jak3 and
mediates STAT3 activation (10). The same report also sug-
gested that CD40-mediated ICAM-1 up-regulation is medi-
ated through the Jak3ySTAT3 pathway. However, we did not
observe any differences in the abilities of ICAM-1 up-
regulation between wild-type CD40 and the mutant CD40
carrying the P207A mutation, which was characterized previ-
ously as abolishing Jak3 association with the CD40ct. One
possible explanation is that the mutations used previously,
such as T234A, also abolish TRAF2 binding. However, further
studies are required to confirm the role of the Jak3ySTAT3
pathway in CD40-mediated ICAM-1 induction.
Upstream of the ICAM-1 promoter, there is an NF-kB-
binding site that has been reported to mediate NF-kB-
dependent ICAM-1 transcription (21). By using luciferase
reporter genes driven by either the wild-type ICAM-1 pro-
moter or the mutant ICAM-1 promoter carrying point muta-
tions in the NF-kB-binding site, we found that the NF-kB-
binding site in the upstream ICAM-1 promoter is critical for
CD40-mediated up-regulation of the ICAM-1 gene, suggesting
that the CD40-induced NF-kB activities may directly target the
ICAM-1 promoter and be involved in transcriptional activa-
tion of the ICAM-1 gene. In combination with the existing
data, we propose a CD40-mediated signal transduction path-
way that cascades from CD40L to CD40 to TRAF2 to phos-
phorylation of IkB to activation of NF-kB and, finally, to
ICAM-1.
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